Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Madrigal Pharmaceuticals, Inc. (MDGL)
USD542.21
+5.35 (+1.00%)
US NASDAQ Healthcare Biotechnology
Address
Four Tower Bridge 19428
West Conshohocken, PA, US
West Conshohocken, PA, US
CEO
William J. Sibold
Website
madrigalpharma.com
IPO
2007-02-06
CIK 1157601 ISIN US5588681057
Description
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD542.21
+5.35 (+1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
328.7K
Beta
-1.06
Float Shares
20.84M
Free Float %
90.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.55% | -6.94% | -4.35% | +4.91% | -6.03% | -14.65% | +65.26% | +69.68% | +274.52% | +3,127.47% | +56.23% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (23 ratings, all time)
Buy
Price Targets & DCF
Current price
542.21
Low
571.00
+5.3%
Consensus
705.10
+30.0%
Median
644.50
+18.9%
High
964.00
+77.8%
DCF (Unlevered)
3,011.36
+455.4%
DCF (Levered)
1,342.75
+147.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 11 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 12 |
671.75
+23.9%
|
| All Time | 31 |
456.58
-15.8%
|
Quality scores
Altman Z-Score
8.80
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+432.1% ★ Q1'26: +126.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+41.3% ★ Q1'26: +2.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-30.9% Q1'26: -55.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-27.8% Q1'26: -29.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -509.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.5% Q1'26: +31.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.34× Q1'26: -0.94× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 8 EPS Ana. |
Dec 2027 11 Rev. Ana. 9 EPS Ana. |
Dec 2028 11 Rev. Ana. 11 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.58M
est: 7.78M (-2.5%)
|
—
est: 22.17M (-100.0%)
|
—
est: 9.18M (-100.0%)
|
180.13M
est: 174.63M (+3.1%)
|
958.40M
est: 949.55M (+0.9%)
|
1.50B
1.48B – 1.54B
+57.5% YoY
|
2.22B
1.94B – 2.41B
+48.4% YoY
|
3.00B
2.99B – 3.00B
+35.0% YoY
|
3.94B
3.59B – 4.35B
+31.7% YoY
|
4.94B
4.50B – 5.45B
+25.3% YoY
|
| EBITDA |
-43.97M
est: -39.58M (-11.1%)
|
-83.84M
est: -92.51M (+9.4%)
|
-201.77M
est: -175.89M (-14.7%)
|
-450.13M
est: 60.22M (-847.5%)
|
-264.47M
est: 327.41M (-180.8%)
|
515.52M
508.60M – 529.36M
+57.5% YoY
|
765.10M
668.17M – 830.88M
+48.4% YoY
|
1.03B
1.03B – 1.03B
+35.0% YoY
|
1.36B
1.24B – 1.50B
+31.7% YoY
|
1.70B
1.55B – 1.88B
+25.3% YoY
|
| EBIT |
-45.43M
est: -40.90M (-11.1%)
|
-83.95M
est: -92.62M (+9.4%)
|
-202.24M
est: -176.29M (-14.7%)
|
-451.22M
est: 60.16M (-850.0%)
|
-265.98M
est: 327.12M (-181.3%)
|
515.05M
508.14M – 528.88M
+57.5% YoY
|
764.41M
667.56M – 830.13M
+48.4% YoY
|
1.03B
1.03B – 1.03B
+35.0% YoY
|
1.36B
1.24B – 1.50B
+31.7% YoY
|
1.70B
1.55B – 1.88B
+25.3% YoY
|
| Net Income |
-47.38M
est: -42.67M (-11.0%)
|
-83.95M
est: -81.79M (-2.6%)
|
-202.24M
est: -172.74M (-17.1%)
|
-465.89M
est: -527.82M (+11.7%)
|
-288.28M
est: -239.82M (-20.2%)
|
-196.38M
-218.63M – -15.77M
+18.1% YoY
|
316.70M
50.00M – 365.26M
+261.3% YoY
|
796.75M
361.70M – 1.04B
+151.6% YoY
|
967.01M
854.90M – 1.10B
+21.4% YoY
|
1.39B
1.23B – 1.57B
+43.4% YoY
|
| SGA |
11.55M
est: 9.98M (+15.7%)
|
22.65M
est: 22.06M (+2.7%)
|
21.86M
est: 11.78M (+85.6%)
|
435.06M
est: 218.79M (+98.8%)
|
813.83M
est: 1.19B (-31.6%)
|
1.87B
1.85B – 1.92B
+57.5% YoY
|
2.78B
2.43B – 3.02B
+48.4% YoY
|
3.75B
3.75B – 3.76B
+35.0% YoY
|
4.94B
4.50B – 5.45B
+31.7% YoY
|
6.19B
5.64B – 6.83B
+25.3% YoY
|
| EPS |
-35.14
est: -33.86 (-3.8%)
|
-4.73
est: -5.51 (+14.1%)
|
-13.09
est: -12.93 (-1.3%)
|
-21.90
est: -23.40 (+6.4%)
|
-12.85
est: -11.04 (-16.4%)
|
-6.55
-9.75 – -0.70
+40.7% YoY
|
10.47
2.23 – 16.28
+260.0% YoY
|
26.60
16.12 – 46.23
+153.9% YoY
|
43.10
38.11 – 48.89
+62.1% YoY
|
61.80
54.64 – 70.09
+43.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-257.50M
OE per share TTM
-9.80
Owner's Yield
-1.64%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
90
Total invested
232.49M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RTW Investments, LP | 1.99M | 9.20% | — | 1.99M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 2 | Roderick Wong, M.D. | 1.99M | 9.20% | — | 1.99M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 3 | Janus Henderson Group plc | 1.91M | 10.30% | — | 1.91M | — | 1.91M | IA, HC | Jersey, Channel Islands | 2023-09-08 | ↗ |
| 4 | Baker Bros. Advisors (GP) LLC | 1.55M | 8.40% | 1.55M | — | 1.55M | — | HC, OO | Delaware | 2023-06-20 | ↗ |
| 5 | Baker Bros. Advisors LP | 1.55M | 8.40% | 1.55M | — | 1.55M | — | IA, PN | Delaware | 2023-06-20 | ↗ |
| 6 | Felix J. Baker | 1.55M | 8.40% | 1.55M | — | 1.55M | — | HC, IN | United States | 2023-06-20 | ↗ |
| 7 | Julian C. Baker | 1.55M | 8.40% | 1.55M | — | 1.55M | — | HC, IN | United States | 2023-06-20 | ↗ |
| 8 | Avoro Capital Advisors LLC | 1.43M | 8.30% | 1.43M | — | 1.43M | — | IA, OO | Delaware | 2022-02-11 | ↗ |
| 9 | Behzad Aghazadeh | 1.43M | 8.30% | 1.43M | — | 1.43M | — | IN | United States | 2022-02-11 | ↗ |
| 10 | Wellington Group Holdings LLP | 1.32M | 7.73% | — | 1.21M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 11 | Wellington Investment Advisors Holdings LLP | 1.32M | 7.73% | — | 1.21M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 12 | Wellington Management Group LLP | 1.32M | 7.73% | — | 1.21M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 13 | STATE STREET CORPORATION | 1.26M | 7.37% | — | 1.23M | — | 1.26M | HC | BOSTON, MASSACHUSETTS | 2023-02-02 | ↗ |
| 14 | Wellington Management Company LLP | 1.24M | 7.26% | — | 1.19M | — | — | IA | Delaware | 2022-02-04 | ↗ |
| 15 | Armistice Capital, LLC | 1.12M | 6.60% | — | 1.12M | — | 1.12M | IA, OO | Delaware | 2022-02-15 | ↗ |
| 16 | Steven Boyd | 1.12M | 6.60% | — | 1.12M | — | 1.12M | HC, IN | Delaware | 2022-02-15 | ↗ |
| 17 | The Vanguard Group - 23-1945930 | 1.12M | 6.57% | — | 21.6K | 1.09M | 30.6K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 18 | Arthur Cohen | 1.09M | 7.10% | — | 1.09M | — | 1.09M | IN | Cayman Islands | 2020-02-14 | ↗ |
| 19 | HealthCor Associates, LLC | 1.09M | 7.10% | — | 1.09M | — | 1.09M | OO | Cayman Islands | 2020-02-14 | ↗ |
| 20 | Joseph Healey | 1.09M | 7.10% | — | 1.09M | — | 1.09M | IN | Cayman Islands | 2020-02-14 | ↗ |
| 21 | SSGA FUNDS MANAGEMENT, INC. | 1.03M | 6.01% | — | 1.03M | — | 1.03M | IA | BOSTON, MASSACHUSETTS | 2023-02-02 | ↗ |
| 22 | PAULSON & CO. INC. | 1.00M | 5.10% | — | — | 1.00M | — | IA | DELAWARE | 2023-11-13 | ↗ |
| 23 | (1) BlackRock, Inc. | 949.5K | 5.60% | 928.4K | — | 949.5K | — | HC | Delaware | 2022-02-03 | ↗ |
| 24 | David Kroin | 917.8K | 5.37% | — | 917.8K | — | — | HC, IN | United States | 2022-05-19 | ↗ |
| 25 | Deep Track Biotechnology Master Fund, Ltd. | 917.8K | 5.37% | — | 917.8K | — | — | CO | Cayman Islands | 2022-05-19 | ↗ |
| 26 | Deep Track Capital, LP | 917.8K | 5.37% | — | 917.8K | — | — | IA, OO | Delaware | 2022-05-19 | ↗ |
| 27 | HealthCor Group, LLC | 628.8K | 4.10% | — | 628.8K | — | 628.8K | OO | Cayman Islands | 2020-02-14 | ↗ |
| 28 | Fred B. Craves | 567.6K | 2.90% | 566.4K | 1.3K | 566.4K | 1.3K | IN | — | 2023-12-13 | ↗ |
| 29 | HealthCor Offshore II GP, LLC | 305.5K | 2.00% | — | 305.5K | — | 305.5K | OO | Cayman Islands | 2020-02-14 | ↗ |
| 30 | HealthCor Sanatate Offshore Master Fund, L.P. | 305.5K | 2.00% | — | 305.5K | — | 305.5K | PN | Cayman Islands | 2020-02-14 | ↗ |
| 31 | HealthCor Market Neutral Master Fund, L.P. | 3.8K | 0.00% | — | 3.8K | — | 3.8K | PN | Cayman Islands | 2020-02-14 | ↗ |
| 32 | Bay City Capital LLC | 1.3K | 0.00% | — | 1.3K | — | 1.3K | OO | — | 2023-12-13 | ↗ |
| 33 | 95-1411037 | 13.00 | 2.80% | 466.4K | — | 466.4K | — | IA | Delaware | 2021-07-09 | ↗ |
| 34 | Bay City Capital Fund IV, L.P. | — | 0.00% | — | — | — | — | PN | — | 2023-12-13 | ↗ |
| 35 | Bay City Capital Management IV LLC | — | 0.00% | — | — | — | — | OO | — | 2023-12-13 | ↗ |
| 36 | HealthCor Management, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
90
-322 vs prev Q
New positions
13
Closed positions
313
Increased
38
Reduced
23
Put/Call ratio
0.00
Calls held
2.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 2.14M +— (+0.0%) | 1.25B +264.9M (+27.0%) | 9.53% -0.118 pp | 7.30% +0.204 pp | USD195.24 +198.3% | 38 qtrs — |
| 2 | RTW INVESTMENTS, LP | 1.99M +— (+0.0%) | 1.16B +246.6M (+27.0%) | 8.87% -0.110 pp | 11.63% +0.363 pp | USD265.29 +119.5% | 11 qtrs — |
| 3 | VANGUARD GROUP INC | 1.81M -3.2K (-0.2%) | 1.05B +222.3M (+26.7%) | 8.05% -0.114 pp | 0.02% +0.003 pp | USD178.74 +225.8% | 38 qtrs — |
| 4 | AVORO CAPITAL ADVISORS LLC | 1.81M -25.5K (-1.4%) | 1.05B +211.9M (+25.2%) | 8.04% -0.215 pp | 10.12% -0.748 pp | USD171.91 +238.7% | 31 qtrs — |
| 5 | PAULSON & CO. INC. | 1.71M -200.0K (-10.5%) | 994.36M +119.5M (+13.7%) | 7.59% -0.995 pp | 30.48% +1.019 pp | USD235.69 +147.1% | 11 qtrs — |
| 6 | BLACKROCK, INC. | 1.64M +85.0K (+5.5%) | 957.80M +242.4M (+33.9%) | 7.32% +0.292 pp | 0.02% +0.004 pp | USD251.33 +131.7% | 6 qtrs — |
| 7 | JANUS HENDERSON GROUP PLC | 1.58M -257.8K (-14.0%) | 918.20M +72.9M (+8.6%) | 7.05% -1.249 pp | 0.41% +0.025 pp | USD185.36 +214.2% | 14 qtrs — |
| 8 | STATE STREET CORP | 583.0K -75.1K (-11.4%) | 339.51M +37.7M (+12.5%) | 2.59% -0.370 pp | 0.01% +0.001 pp | USD180.15 +223.3% | 35 qtrs — |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 461.4K +56.9K (+14.1%) | 268.69M +83.2M (+44.8%) | 2.05% +0.231 pp | 0.05% +0.015 pp | USD469.98 +23.9% | 6 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 451.7K +5.5K (+1.2%) | 263.11M +58.4M (+28.5%) | 2.01% 0.000 pp | 0.02% +0.003 pp | USD195.56 +197.8% | 38 qtrs — |
| 11 | FMR LLC | 439.4K +38.3K (+9.5%) | 255.88M +71.9M (+39.1%) | 1.95% +0.148 pp | 0.01% +0.004 pp | USD247.53 +135.3% | 34 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 416.0K +171.7K (+70.3%) | 242.27M +130.2M (+116.2%) | 1.85% +0.750 pp | 0.02% +0.010 pp | USD384.94 +51.3% | 37 qtrs — |
| 13 | INVESCO LTD. | 365.3K +65.7K (+21.9%) | 212.74M +75.3M (+54.8%) | 1.62% +0.276 pp | 0.03% +0.011 pp | USD383.31 +51.9% | 24 qtrs — |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 354.2K -57.6K (-14.0%) | 206.28M +17.4M (+9.2%) | 1.58% -0.279 pp | 0.58% +0.087 pp | USD330.99 +75.9% | 5 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 313.7K -38.9K (-11.0%) | 182.66M +21.0M (+13.0%) | 1.40% -0.192 pp | 0.02% +0.002 pp | USD230.96 +152.1% | 32 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 305.8K -80.3K (-20.8%) | 178.11M +1.0M (+0.6%) | 1.36% -0.378 pp | 0.02% +0.000 pp | USD329.25 +76.9% | 33 qtrs — |
| 17 | POLAR CAPITAL HOLDINGS PLC | 270.2K +5.0K (+1.9%) | 157.32M +35.7M (+29.4%) | 1.20% +0.008 pp | 0.61% +0.023 pp | USD315.47 +84.6% | 8 qtrs — |
| 18 | ARMISTICE CAPITAL, LLC | 265.7K +145.7K (+121.5%) | 154.73M +99.7M (+181.2%) | 1.18% +0.642 pp | 1.84% +1.025 pp | USD446.24 +30.5% | 38 qtrs — |
| 19 | HOOD RIVER CAPITAL MANAGEMENT LLC | 247.6K +4.8K (+2.0%) | 144.16M +32.8M (+29.5%) | 1.10% +0.008 pp | 1.58% +0.266 pp | USD324.36 +79.5% | 5 qtrs — |
| 20 | LORD, ABBETT & CO. LLC | 244.8K +142.7K (+139.7%) | 142.56M +95.7M (+204.3%) | 1.09% +0.629 pp | 0.44% +0.298 pp | USD483.66 +20.4% | 5 qtrs — |
| 21 | ALKEON CAPITAL MANAGEMENT LLC | 240.0K +120.0K (+100.0%) | 139.76M +84.7M (+153.9%) | 1.07% +0.527 pp | 0.22% +0.140 pp | USD520.50 +11.9% | 2 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 219.1K +5.4K (+2.5%) | 127.59M +29.6M (+30.2%) | 0.97% +0.012 pp | 0.02% +0.004 pp | USD262.64 +121.7% | 35 qtrs — |
| 23 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 198.7K -7.6K (-3.7%) | 115.71M +21.1M (+22.3%) | 0.88% -0.045 pp | 0.17% +0.039 pp | USD215.78 +169.9% | 22 qtrs — |
| 24 | NORGES BANK | 196.4K +196.4K (+100.0%) | 114.37M +114.4M (+100.0%) | 0.87% +0.874 pp | 0.01% +0.012 pp | USD582.34 +0.0% | 1 qtrs NEW |
| 25 | DEUTSCHE BANK AG\ | 192.1K +154.8K (+414.5%) | 111.87M +94.7M (+553.2%) | 0.85% +0.686 pp | 0.04% +0.031 pp | USD521.04 +11.8% | 35 qtrs — |
| 26 | AMERICAN CENTURY COMPANIES INC | 185.1K +19.5K (+11.8%) | 107.80M +31.8M (+41.9%) | 0.82% +0.078 pp | 0.05% +0.016 pp | USD295.12 +97.3% | 12 qtrs — |
| 27 | PICTET ASSET MANAGEMENT HOLDING SA | 181.9K -9.8K (-5.1%) | 106.02M +18.3M (+20.9%) | 0.81% -0.054 pp | 0.10% +0.018 pp | USD219.21 +165.7% | 10 qtrs — |
| 28 | FIERA CAPITAL CORP | 169.5K +41.7K (+32.6%) | 98.68M +40.1M (+68.3%) | 0.75% +0.178 pp | 0.31% +0.124 pp | USD361.14 +61.3% | 7 qtrs — |
| 29 | NORTHERN TRUST CORP | 151.8K -8.2K (-5.1%) | 88.40M +15.0M (+20.5%) | 0.68% -0.045 pp | 0.01% +0.002 pp | USD172.23 +238.1% | 36 qtrs — |
| 30 | MORGAN STANLEY | 150.5K -99.2K (-39.7%) | 87.62M -26.9M (-23.5%) | 0.67% -0.455 pp | 0.01% -0.002 pp | USD264.54 +120.1% | 38 qtrs — |
| 31 | ERSTE ASSET MANAGEMENT GMBH | 141.1K -60.0K (-29.8%) | 82.32M -6.8M (-7.6%) | 0.63% -0.278 pp | 0.69% -0.170 pp | USD194.62 +199.2% | 13 qtrs — |
| 32 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 139.6K +1.9K (+1.4%) | 81.31M +18.1M (+28.7%) | 0.62% +0.001 pp | 4.17% +0.478 pp | USD145.65 +299.8% | 38 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 136.9K +39.1K (+40.0%) | 79.70M +34.9M (+77.7%) | 0.61% +0.169 pp | 0.01% +0.006 pp | USD333.58 +74.6% | 35 qtrs — |
| 34 | JANE STREET GROUP, LLC | 128.4K -27.7K (-17.7%) | 74.77M +3.2M (+4.4%) | 0.57% -0.132 pp | 0.01% +0.000 pp | USD264.54 +120.1% | 6 qtrs — |
| 35 | POINT72 ASSET MANAGEMENT, L.P. | 126.4K +85.2K (+206.6%) | 73.63M +54.7M (+289.3%) | 0.56% +0.377 pp | 0.08% +0.051 pp | USD496.66 +17.3% | 4 qtrs — |
| 36 | WOODLINE PARTNERS LP | 125.7K +21.8K (+21.0%) | 73.18M +25.5M (+53.6%) | 0.56% +0.091 pp | 0.28% +0.059 pp | USD342.63 +70.0% | 8 qtrs — |
| 37 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 121.8K -20.2K (-14.2%) | 70.93M +5.8M (+8.9%) | 0.54% -0.098 pp | 0.01% +0.001 pp | USD355.63 +63.7% | 31 qtrs — |
| 38 | NUVEEN, LLC | 118.4K +44.6K (+60.6%) | 68.93M +35.1M (+103.9%) | 0.53% +0.195 pp | 0.02% +0.009 pp | USD460.60 +26.4% | 4 qtrs — |
| 39 | DRIEHAUS CAPITAL MANAGEMENT LLC | 111.7K -4.3K (-3.7%) | 65.03M +11.8M (+22.2%) | 0.50% -0.026 pp | 0.44% +0.061 pp | USD458.66 +27.0% | 2 qtrs — |
| 40 | CITADEL ADVISORS LLC | 104.9K +41.1K (+64.4%) | 61.09M +31.8M (+108.8%) | 0.47% +0.179 pp | 0.01% +0.005 pp | USD417.60 +39.4% | 31 qtrs — |
| 41 | UBS GROUP AG | 102.6K -114.7K (-52.8%) | 59.77M -39.9M (-40.0%) | 0.46% -0.522 pp | 0.01% -0.006 pp | USD279.83 +108.1% | 38 qtrs — |
| 42 | 683 CAPITAL MANAGEMENT, LLC | 99.0K -53.0K (-34.9%) | 57.65M -12.1M (-17.3%) | 0.44% -0.244 pp | 2.51% -1.134 pp | USD304.58 +91.2% | 12 qtrs — |
| 43 | BIOIMPACT CAPITAL LLC | 96.8K -3.6K (-3.6%) | 56.36M +10.3M (+22.4%) | 0.43% -0.022 pp | 6.45% -1.091 pp | USD331.23 +75.8% | 15 qtrs — |
| 44 | D. E. SHAW & CO., INC. | 88.6K -7.6K (-7.9%) | 51.57M +7.5M (+16.9%) | 0.39% -0.039 pp | 0.03% +0.003 pp | USD323.09 +80.2% | 21 qtrs — |
| 45 | FRANKLIN RESOURCES INC | 86.1K +10.5K (+13.9%) | 50.13M +15.5M (+44.6%) | 0.38% +0.043 pp | 0.01% +0.004 pp | USD367.50 +58.5% | 8 qtrs — |
| 46 | TRI LOCUM PARTNERS LP | 86.0K +18.3K (+27.1%) | 50.09M +19.0M (+61.3%) | 0.38% +0.078 pp | 6.50% -0.633 pp | USD348.36 +67.2% | 13 qtrs — |
| 47 | RENAISSANCE TECHNOLOGIES LLC | 83.9K -36.8K (-30.5%) | 48.84M -6.5M (-11.8%) | 0.37% -0.170 pp | 0.08% +0.003 pp | USD442.79 +31.5% | 6 qtrs — |
| 48 | ARROWMARK COLORADO HOLDINGS LLC | 82.6K -40.6K (-33.0%) | 48.12M -8.4M (-14.9%) | 0.37% -0.188 pp | 1.06% +0.009 pp | USD281.35 +107.0% | 8 qtrs — |
| 49 | NEW YORK STATE COMMON RETIREMENT FUND | 75.9K +6.7K (+9.6%) | 44.22M +12.4M (+39.2%) | 0.34% +0.026 pp | 0.06% +0.018 pp | USD304.90 +91.0% | 35 qtrs — |
| 50 | SQUAREPOINT OPS LLC | 74.9K +45.0K (+150.3%) | 43.64M +29.9M (+217.8%) | 0.33% +0.199 pp | 0.05% +0.033 pp | USD523.97 +11.1% | 7 qtrs — |
| 51 | BNP PARIBAS ARBITRAGE, SNC | 73.7K +3.0K (+4.2%) | 42.92M +10.5M (+32.3%) | 0.33% +0.009 pp | 0.02% +0.002 pp | USD312.60 +86.3% | 35 qtrs — |
| 52 | FIRST LIGHT ASSET MANAGEMENT, LLC | 66.8K +55.3K (+479.2%) | 38.92M +33.6M (+635.4%) | 0.30% +0.245 pp | 2.98% +2.477 pp | USD560.99 +3.8% | 2 qtrs — |
| 53 | RAYMOND JAMES FINANCIAL INC | 66.7K -3.9K (-5.5%) | 38.91M +6.5M (+20.2%) | 0.30% -0.021 pp | 0.01% +0.002 pp | USD341.79 +70.4% | 5 qtrs — |
| 54 | VOYA INVESTMENT MANAGEMENT LLC | 64.3K +4.8K (+8.1%) | 37.42M +10.2M (+37.3%) | 0.29% +0.018 pp | 0.04% +0.010 pp | USD337.11 +72.7% | 32 qtrs — |
| 55 | CANDRIAM S.C.A. | 63.9K +13.9K (+27.9%) | 37.22M +14.3M (+62.4%) | 0.28% +0.059 pp | 0.19% +0.065 pp | USD373.22 +56.0% | 4 qtrs — |
| 56 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 58.3K -27.5K (-32.0%) | 33.95M -5.4M (-13.7%) | 0.26% -0.127 pp | 0.09% -0.035 pp | USD251.19 +131.8% | 18 qtrs — |
| 57 | JAIN GLOBAL LLC | 52.7K +52.7K (+100.0%) | 30.70M +30.7M (+100.0%) | 0.23% +0.235 pp | 0.15% +0.148 pp | USD582.34 +0.0% | 1 qtrs NEW |
| 58 | ENSIGN PEAK ADVISORS, INC | 51.0K -2.3K (-4.2%) | 29.71M +5.3M (+21.6%) | 0.23% -0.013 pp | 0.05% +0.012 pp | USD305.70 +90.5% | 17 qtrs — |
| 59 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 50.6K +53.0 (+0.1%) | 29.48M +6.3M (+27.1%) | 0.23% -0.003 pp | 0.08% +0.009 pp | USD226.18 +157.5% | 11 qtrs — |
| 60 | EULAV ASSET MANAGEMENT | 49.0K -2.0K (-3.9%) | 28.53M +5.1M (+22.0%) | 0.22% -0.012 pp | 0.76% +0.218 pp | USD349.85 +66.5% | 9 qtrs — |
| 61 | RUSSELL INVESTMENTS GROUP, LTD. | 48.2K +3.3K (+7.3%) | 28.05M +7.5M (+36.2%) | 0.21% +0.012 pp | 0.03% +0.007 pp | USD373.13 +56.1% | 12 qtrs — |
| 62 | CANADA PENSION PLAN INVESTMENT BOARD | 46.1K +37.1K (+412.4%) | 26.86M +22.7M (+550.6%) | 0.21% +0.165 pp | 0.02% +0.015 pp | USD540.08 +7.8% | 5 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 43.5K +5.6K (+14.9%) | 25.31M +8.0M (+45.9%) | 0.19% +0.023 pp | 0.00% +0.001 pp | USD298.17 +95.3% | 38 qtrs — |
| 64 | JPMORGAN CHASE & CO | 40.1K -7.7K (-16.2%) | 23.34M +1.4M (+6.4%) | 0.18% -0.037 pp | 0.00% +0.000 pp | USD245.14 +137.6% | 38 qtrs — |
| 65 | MARSHALL WACE, LLP | 39.6K +38.9K (+5,554.0%) | 23.05M +22.7M (+7,078.6%) | 0.18% +0.173 pp | 0.02% +0.021 pp | USD577.31 +0.9% | 12 qtrs — |
| 66 | EMERALD ADVISERS, LLC | 38.9K -11.8K (-23.3%) | 22.66M -610.4K (-2.6%) | 0.17% -0.055 pp | 0.70% -0.048 pp | USD283.88 +105.1% | 13 qtrs — |
| 67 | BARCLAYS PLC | 38.7K -1.6K (-3.9%) | 22.55M +14.0M (+163.8%) | 0.17% -0.009 pp | 0.01% +0.003 pp | USD249.35 +133.5% | 35 qtrs — |
| 68 | ATIKA CAPITAL MANAGEMENT LLC | 34.0K +34.0K (+100.0%) | 19.80M +19.8M (+100.0%) | 0.15% +0.151 pp | 2.08% +2.085 pp | USD582.34 +0.0% | 1 qtrs NEW |
| 69 | SEGALL BRYANT & HAMILL, LLC | 33.5K +11.0K (+49.0%) | 19.52M +9.2M (+89.2%) | 0.15% +0.048 pp | 0.26% +0.127 pp | USD499.36 +16.6% | 2 qtrs — |
| 70 | GILDER GAGNON HOWE & CO LLC | 33.5K +2.6K (+8.5%) | 19.49M +5.3M (+37.7%) | 0.15% +0.010 pp | 0.21% +0.062 pp | USD281.31 +107.0% | 8 qtrs — |
| 71 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 32.9K +32.9K (+100.0%) | 19.14M +19.1M (+100.0%) | 0.15% +0.146 pp | 0.06% +0.064 pp | USD582.34 +0.0% | 1 qtrs NEW |
| 72 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 31.3K +7.2K (+29.8%) | 18.22M +7.2M (+64.8%) | 0.14% +0.031 pp | 0.01% +0.004 pp | USD325.48 +78.9% | 12 qtrs — |
| 73 | AFFINITY ASSET ADVISORS, LLC | 31.1K -83.9K (-72.9%) | 18.13M -34.6M (-65.6%) | 0.14% -0.379 pp | 1.03% -3.562 pp | USD246.64 +136.1% | 17 qtrs — |
| 74 | GROUPAMA ASSET MANAGMENT | 30.6K +3.2K (+11.6%) | 17.83M +5.2M (+41.7%) | 0.14% +0.013 pp | 0.26% +0.077 pp | USD330.66 +76.1% | 9 qtrs — |
| 75 | AMERIPRISE FINANCIAL INC | 29.3K +16.3K (+125.3%) | 17.05M +11.1M (+186.1%) | 0.13% +0.072 pp | 0.00% +0.003 pp | USD467.46 +24.6% | 13 qtrs — |
| 76 | SCHRODER INVESTMENT MANAGEMENT GROUP | 29.1K +12.4K (+74.9%) | 16.96M +9.6M (+130.4%) | 0.13% +0.054 pp | 0.01% +0.007 pp | USD417.60 +39.4% | 9 qtrs — |
| 77 | SWISS NATIONAL BANK | 28.6K +680.0 (+2.4%) | 16.64M +3.8M (+30.1%) | 0.13% +0.002 pp | 0.01% +0.003 pp | USD164.91 +253.1% | 33 qtrs — |
| 78 | STEADFAST CAPITAL MANAGEMENT LP | 26.9K -3.0K (-9.9%) | 15.64M +2.0M (+14.4%) | 0.12% -0.015 pp | 0.27% +0.030 pp | USD458.66 +27.0% | 2 qtrs — |
| 79 | RHEOS CAPITAL WORKS INC. | 26.2K -17.0K (-39.3%) | 15.27M -4.6M (-23.0%) | 0.12% -0.078 pp | 0.98% -0.131 pp | USD255.74 +127.7% | 8 qtrs — |
| 80 | EMERALD MUTUAL FUND ADVISERS TRUST | 25.0K -10.1K (-28.8%) | 14.56M -1.5M (-9.6%) | 0.11% -0.047 pp | 0.71% -0.122 pp | USD285.40 +104.0% | 13 qtrs — |
| 81 | FIRST TRUST ADVISORS LP | 24.8K +21.0K (+554.0%) | 14.45M +12.7M (+730.3%) | 0.11% +0.093 pp | 0.01% +0.009 pp | USD549.38 +6.0% | 6 qtrs — |
| 82 | UBS ASSET MANAGEMENT AMERICAS INC | 23.8K +370.0 (+1.6%) | 13.89M +3.1M (+29.0%) | 0.11% +0.000 pp | 0.00% +0.001 pp | USD283.36 +105.5% | 31 qtrs — |
| 83 | RHUMBLINE ADVISERS | 23.7K -3.6K (-13.1%) | 13.80M +1.3M (+10.3%) | 0.11% -0.017 pp | 0.01% +0.001 pp | USD184.39 +215.8% | 33 qtrs — |
| 84 | CITIGROUP INC | 23.3K +13.7K (+141.8%) | 13.58M +9.2M (+207.0%) | 0.10% +0.060 pp | 0.01% +0.004 pp | USD453.34 +28.5% | 35 qtrs — |
| 85 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 23.2K -65.3K (-73.8%) | 13.53M -27.1M (-66.7%) | 0.10% -0.295 pp | 0.02% -0.044 pp | USD316.00 +84.3% | 5 qtrs — |
| 86 | SEI INVESTMENTS CO | 23.1K +4.0K (+20.7%) | 13.44M +4.7M (+53.3%) | 0.10% +0.017 pp | 0.01% +0.004 pp | USD353.90 +64.5% | 13 qtrs — |
| 87 | ALLIANCEBERNSTEIN L.P. | 21.9K -13.8K (-38.6%) | 12.76M -3.6M (-22.1%) | 0.10% -0.063 pp | 0.00% -0.001 pp | USD332.25 +75.3% | 33 qtrs — |
| 88 | TAO CAPITAL MANAGEMENT LP | 21.0K -20.0K (-48.8%) | 12.23M -6.6M (-35.0%) | 0.09% -0.091 pp | 10.53% -3.698 pp | USD157.52 +269.7% | 22 qtrs — |
| 89 | NOMURA HOLDINGS INC | 20.9K -900.0 (-4.1%) | 12.17M +2.2M (+21.7%) | 0.09% -0.005 pp | 0.02% +0.001 pp | USD366.34 +59.0% | 5 qtrs — |
| 90 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 19.7K +1.2K (+6.6%) | 11.45M +3.0M (+35.3%) | 0.09% +0.004 pp | 0.02% +0.004 pp | USD250.97 +132.0% | 12 qtrs — |
| 91 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 19.6K +1.3K (+7.1%) | 11.38M +3.0M (+36.0%) | 0.09% +0.005 pp | 1.06% +0.138 pp | USD466.88 +24.7% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 129 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Tema Cardiovascular and Metabolic ETF HRTS | 1.47% | 804.5K | 0.99% |
| 2 | Virtus Biotech ETF BBP | 1.44% | 1.42M | 0.34% |
| 3 | First Trust Innovation Leaders ETF ILDR | 1.22% | 3.68M | 0.75% |
| 4 | Global X - Guru Index ETF GURU | 1.07% | 676.8K | 0.75% |
| 5 | Goldman Sachs Future Health Care Equity ETF GDOC | 1.06% | 201.7K | 0.75% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 1.05% | 377.7K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 1.05% | 113.68M | 0.35% |
| 8 | iShares Biotechnology ETF IBB | 0.90% | 84.06M | 0.44% |
| 9 | First Trust Health Care AlphaDEX Fund FXH | 0.87% | 8.64M | 0.61% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.86% | 628.0K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.20
Bearish
Ratio by volume
1.21
Neutral
Buys
18
Sells
89
Shares acquired
127.5K
Shares disposed
105.6K
Cash buys
—
Cash sales
83.00
Net activity
+21,939
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | Taub Rebecca | Director | S-Sale | D | Common Stock | 491 | 431.94 | 212.1K | 452,213 | D | ↗ |
| 2026-03-06 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 1,663 | 431.94 | 718.3K | 161,829 | D | ↗ |
| 2026-03-06 | Kelley Shannon T | Officer | S-Sale | D | Common Stock | 360 | 431.94 | 155.5K | 12,138 | D | ↗ |
| 2026-03-06 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 419 | 431.94 | 181.0K | 12,692 | D | ↗ |
| 2026-03-06 | Dier Mardi | Officer | S-Sale | D | Common Stock | 160 | 434.20 | 69.5K | 12,690 | D | ↗ |
| 2026-03-04 | Soergel David | Officer | A-Award | A | Stock Option (Right to Buy) | 5,467 | 434.80 | 2.38M | 5,467 | D | ↗ |
| 2026-03-04 | Sibold William John | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 18,743 | 434.80 | 8.15M | 18,743 | D | ↗ |
| 2026-03-04 | Kelley Shannon T | Officer | A-Award | A | Common Stock | 4,017 | 0.00 | — | 12,498 | D | ↗ |
| 2026-03-04 | Huntsman Carole | Officer | A-Award | A | Common Stock | 3,989 | 0.00 | — | 13,111 | D | ↗ |
| 2026-03-04 | Dier Mardi | Officer | A-Award | A | Common Stock | 5,215 | 0.00 | — | 14,472 | D | ↗ |
| 2026-03-02 | Dier Mardi | Officer | S-Sale | D | Common Stock | 1,183 | 427.21 | 505.4K | 9,257 | D | ↗ |
| 2026-02-23 | Levy Richard S | Director | M-Exempt | A | Common Stock | 2,500 | 7.36 | 18.4K | 27,697 | D | ↗ |
| 2026-01-26 | Taub Rebecca | Director | S-Sale | D | Common Stock | 647 | 492.42 | 318.6K | 452,704 | D | ↗ |
| 2026-01-26 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 1,577 | 492.42 | 776.5K | 148,497 | D | ↗ |
| 2026-01-26 | Levy Richard S | Director | M-Exempt | A | Common Stock | 4,000 | 16.46 | 65.8K | 25,197 | D | ↗ |
| 2026-01-26 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 340 | 492.42 | 167.4K | 9,692 | D | ↗ |
| 2026-01-20 | Taub Rebecca | Director | S-Sale | D | Common Stock | 2,238 | 490.77 | 1.10M | 453,351 | D | ↗ |
| 2026-01-20 | Kelley Shannon T | Officer | S-Sale | D | Common Stock | 429 | 501.40 | 215.1K | 8,481 | D | ↗ |
| 2026-01-15 | Thakkar Rita | Officer | A-Award | A | Common Stock | 2,398 | 0.00 | — | 2,398 | D | ↗ |
| 2026-01-12 | Thakkar Rita | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-09 | Taub Rebecca | Director | M-Exempt | A | Common Stock | 240 | 15.80 | 3.8K | 455,829 | D | ↗ |
| 2026-01-09 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 1,066 | 526.00 | 560.7K | 193,156 | D | ↗ |
| 2025-12-10 | Taub Rebecca | Director | S-Sale | D | Common Stock | 3,087 | 553.88 | 1.71M | 462,271 | D | ↗ |
| 2025-12-10 | FRIEDMAN PAUL A | Director | M-Exempt | D | Stock Option (Right to Buy) | 24,800 | 15.80 | 391.8K | 24,800 | D | ↗ |
| 2025-12-04 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 2,400 | 575.34 | 1.38M | 150,074 | D | ↗ |
| 2025-12-03 | Sibold William John | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 0.00 | — | 152,474 | D | ↗ |
| 2025-12-02 | Dier Mardi | Officer | S-Sale | D | Common Stock | 258 | 578.83 | 149.3K | 11,874 | D | ↗ |
| 2025-11-21 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 40 | 553.23 | 22.1K | 10,552 | D | ↗ |
| 2025-11-13 | Levy Richard S | Director | M-Exempt | A | Common Stock | 2,500 | 7.36 | 18.4K | 23,697 | D | ↗ |
| 2025-11-05 | BATE KENNETH | Director | S-Sale | D | Common Stock | 30 | 490.98 | 14.7K | 2,627 | D | ↗ |
| 2025-09-09 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 7,279 | 445.63 | 3.24M | 102,474 | D | ↗ |
| 2025-08-21 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 6,485 | 400.03 | 2.59M | 110,884 | D | ↗ |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 5,209 | 380.44 | 1.98M | 1,898,329 | I | ↗ |
| 2025-08-18 | Kelley Shannon T | Officer | S-Sale | D | Common Stock | 42 | 376.62 | 15.8K | 9,173 | D | ↗ |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 515 | 362.39 | 186.6K | 191,894 | I | ↗ |
| 2025-08-15 | BATE KENNETH | Director | S-Sale | D | Common Stock | 2,567 | 365.33 | 937.8K | 5,227 | D | ↗ |
| 2025-08-13 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 3,152 | 366.22 | 1.15M | 296,947 | D | ↗ |
| 2025-08-12 | Taub Rebecca | Director | S-Sale | D | Common Stock | 6,479 | 354.97 | 2.30M | 485,616 | D | ↗ |
| 2025-08-12 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 600 | 359.81 | 215.9K | 187,164 | D | ↗ |
| 2025-08-11 | Taub Rebecca | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,200 | 9.45 | 30.2K | 43,263 | D | ↗ |
| 2025-08-11 | FRIEDMAN PAUL A | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,203 | 9.45 | 30.3K | 172,777 | D | ↗ |
| 2025-08-01 | Brennan Daniel J. | Director | A-Award | A | Common Stock | 967 | 0.00 | — | 967 | D | ↗ |
| 2025-07-18 | Taub Rebecca | Director | M-Exempt | A | Common Stock | 1,000 | 9.45 | 9.5K | 462,044 | D | ↗ |
| 2025-07-18 | FRIEDMAN PAUL A | Director | M-Exempt | A | Common Stock | 1,400 | 9.45 | 13.2K | 188,564 | D | ↗ |
| 2025-07-17 | Taub Rebecca | Director | M-Exempt | A | Common Stock | 2,657 | 9.45 | 25.1K | 463,701 | D | ↗ |
| 2025-07-17 | FRIEDMAN PAUL A | Director | M-Exempt | A | Common Stock | 2,700 | 9.45 | 25.5K | 189,864 | D | ↗ |
| 2025-07-16 | Taub Rebecca | Director | S-Sale | D | Common Stock | 6,441 | 355.61 | 2.29M | 462,424 | D | ↗ |
| 2025-07-16 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 2,110 | 352.67 | 744.1K | 203,318 | D | ↗ |
| 2025-06-20 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 1,290 | 285.73 | 368.6K | 1,290 | D | ↗ |
| 2025-06-20 | FRIEDMAN PAUL A | Director | A-Award | A | Stock Option (Right to Buy) | 1,290 | 285.73 | 368.6K | 1,290 | D | ↗ |
| 2025-06-20 | FOUSE JACQUALYN A | Director | A-Award | A | Stock Option (Right to Buy) | 366 | 285.73 | 104.6K | 366 | D | ↗ |
| 2025-06-20 | Daly James M | Director | A-Award | A | Stock Option (Right to Buy) | 1,290 | 285.73 | 368.6K | 1,290 | D | ↗ |
| 2025-06-20 | BATE KENNETH | Director | A-Award | A | Stock Option (Right to Buy) | 1,290 | 285.73 | 368.6K | 1,290 | D | ↗ |
| 2025-06-20 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Common Stock | 1,430 | 0.00 | — | 1,796,261 | I | ↗ |
| 2025-05-15 | Soergel David | Officer | A-Award | A | Stock Option (Right to Buy) | 12,839 | 291.82 | 3.75M | 12,839 | D | ↗ |
| 2025-04-21 | Soergel David | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-13 | CRAVES FRED B | Director | S-Sale | D | Common Stock | 900 | 324.69 | 292.2K | 353,318 | D | ↗ |
| 2025-03-12 | CRAVES FRED B | Director | S-Sale | D | Common Stock | 2,759 | 331.36 | 914.2K | 353,458 | D | ↗ |
| 2025-03-10 | FOUSE JACQUALYN A | Director | A-Award | A | Common Stock | 894 | 0.00 | — | 894 | D | ↗ |
| 2025-03-10 | Dier Mardi | Officer | S-Sale | D | Common Stock | 258 | 323.04 | 83.3K | 10,440 | D | ↗ |
| 2025-03-05 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 1,077 | 342.90 | 369.3K | 9,841 | D | ↗ |
| 2025-03-05 | Taub Rebecca | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 7,381 | 347.28 | 2.56M | 7,381 | D | ↗ |
| 2025-03-05 | Sibold William John | Director / Officer | A-Award | A | Common Stock | 13,066 | 0.00 | — | 117,369 | D | ↗ |
| 2025-03-05 | Kelley Shannon T | Officer | A-Award | A | Stock Option (Right to Buy) | 5,368 | 347.28 | 1.86M | 5,368 | D | ↗ |
| 2025-03-05 | Huntsman Carole | Officer | A-Award | A | Common Stock | 3,386 | 0.00 | — | 11,990 | D | ↗ |
| 2025-03-05 | Dier Mardi | Officer | A-Award | A | Stock Option (Right to Buy) | 6,374 | 347.28 | 2.21M | 6,374 | D | ↗ |
| 2025-03-03 | Kelley Shannon T | Officer | S-Sale | D | Common Stock | 415 | 335.00 | 139.0K | 7,290 | D | ↗ |
| 2025-03-03 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 300 | 320.21 | 96.1K | 9,867 | D | ↗ |
| 2025-03-03 | Dier Mardi | Officer | S-Sale | D | Common Stock | 774 | 323.54 | 250.4K | 6,914 | D | ↗ |
| 2025-02-28 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 1,052 | 340.99 | 358.7K | 3,903 | D | ↗ |
| 2025-02-27 | Sibold William John | Director / Officer | M-Exempt | D | Performance Restricted Stock Units | 50,000 | 0.00 | — | 0 | D | ↗ |
| 2025-02-27 | Daly James M | Director | S-Sale | D | Common Stock | 14,302 | 347.39 | 4.97M | 2,682 | D | ↗ |
| 2025-02-27 | BATE KENNETH | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,530 | 9.45 | 42.8K | 5,470 | D | ↗ |
| 2025-01-24 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 103 | 335.24 | 34.5K | 4,955 | D | ↗ |
| 2025-01-24 | Taub Rebecca | Director / Officer | S-Sale | D | Common Stock | 648 | 335.24 | 217.2K | 456,662 | D | ↗ |
| 2025-01-24 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 1,584 | 335.24 | 531.0K | 54,303 | D | ↗ |
| 2025-01-24 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 347 | 335.24 | 116.3K | 10,438 | D | ↗ |
| 2025-01-17 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 442 | 273.41 | 120.8K | 5,058 | D | ↗ |
| 2025-01-17 | Taub Rebecca | Director / Officer | S-Sale | D | Common Stock | 1,689 | 273.41 | 461.8K | 457,310 | D | ↗ |
| 2025-01-17 | Kelley Shannon T | Officer | S-Sale | D | Common Stock | 277 | 273.41 | 75.7K | 7,705 | D | ↗ |
| 2024-12-03 | CRAVES FRED B | Director | S-Sale | D | Common Stock | 3,080 | 315.21 | 970.9K | 11,520 | I | ↗ |
| 2024-11-25 | CRAVES FRED B | Director | S-Sale | D | Common Stock | 1,200 | 350.71 | 420.9K | 14,600 | I | ↗ |
| 2024-11-21 | Huntsman Carole | Officer | S-Sale | D | Common Stock | 688 | 316.92 | 218.0K | 10,785 | D | ↗ |
| 2024-11-07 | Levy Richard S | Director | S-Sale | D | Common Stock | 5,000 | 350.00 | 1.75M | 11,012 | D | ↗ |
| 2024-11-01 | Levy Richard S | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 7.36 | 36.8K | 10,000 | D | ↗ |
| 2024-09-13 | CRAVES FRED B | Director | G-Gift | D | Common Stock | 15,000 | 0.00 | — | 360,076 | — | ↗ |
| 2024-09-09 | Sibold William John | Director / Officer | S-Sale | D | Common Stock | 6,363 | 243.83 | 1.55M | 55,887 | — | ↗ |
| 2024-08-15 | Kelley Shannon T | Officer | A-Award | A | Common Stock | 5,215 | 0.00 | — | 7,982 | — | ↗ |
| 2024-08-05 | Kelley Shannon T | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,767 | — | ↗ |
| 2024-06-25 | Levy Richard S | Director | A-Award | A | Common Stock | 714 | 0.00 | — | 11,012 | — | ↗ |
| 2024-06-25 | FRIEDMAN PAUL A | Director | A-Award | A | Common Stock | 714 | 0.00 | — | 186,449 | — | ↗ |
| 2024-06-25 | Daly James M | Director | A-Award | A | Common Stock | 714 | 0.00 | — | 1,912 | — | ↗ |
| 2024-06-25 | CRAVES FRED B | Director | A-Award | A | Stock Option (Right to Buy) | 1,105 | 280.04 | 309.4K | 1,105 | — | ↗ |
| 2024-06-25 | BATE KENNETH | Director | A-Award | A | Stock Option (Right to Buy) | 1,105 | 280.04 | 309.4K | 1,105 | — | ↗ |
| 2024-06-25 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Common Stock | 1,428 | 0.00 | — | 1,794,831 | — | ↗ |
| 2024-06-14 | Waltermire Robert E. | Officer | M-Exempt | A | Common Stock | 1,900 | 87.09 | 165.5K | 7,400 | — | ↗ |
| 2024-06-12 | Waltermire Robert E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,000 | 87.92 | 175.8K | 15,200 | — | ↗ |
| 2024-06-11 | CRAVES FRED B | Director | G-Gift | D | Common Stock | 39,000 | 0.00 | — | 374,362 | — | ↗ |
| 2024-05-21 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 1,036 | 231.34 | 239.7K | 5,500 | — | ↗ |
| 2024-05-14 | CRAVES FRED B | Director | S-Sale | D | Common Stock | 100 | 219.90 | 22.0K | 413,362 | — | ↗ |
| 2024-04-08 | Taub Rebecca | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,676 | 9.45 | 25.3K | 76,564 | — | ↗ |
| 2024-04-08 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 4,866 | 248.59 | 1.21M | 185,735 | — | ↗ |
| 2024-04-05 | Taub Rebecca | Director / Officer | S-Sale | D | Common Stock | 8,817 | 242.61 | 2.14M | 475,345 | — | ↗ |
| 2024-04-05 | FRIEDMAN PAUL A | Director | M-Exempt | D | Stock Option (Right to Buy) | 27,613 | 9.45 | 260.9K | 232,526 | — | ↗ |
| 2024-04-04 | Taub Rebecca | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 18,537 | 9.45 | 175.2K | 106,746 | — | ↗ |
| 2024-04-04 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 5,299 | 242.25 | 1.28M | 192,873 | — | ↗ |
| 2024-04-03 | Taub Rebecca | Director / Officer | S-Sale | D | Common Stock | 18,917 | 245.34 | 4.64M | 461,088 | — | ↗ |
| 2024-04-03 | FRIEDMAN PAUL A | Director | S-Sale | D | Common Stock | 18,806 | 245.34 | 4.61M | 187,556 | — | ↗ |
| 2024-04-02 | Daly James M | Director | M-Exempt | A | Common Stock | 10,912 | 105.08 | 1.15M | 12,110 | — | ↗ |
| 2024-04-02 | BATE KENNETH | Director | S-Sale | D | Common Stock | 2,080 | 244.97 | 509.5K | 2,065 | — | ↗ |
| 2024-04-01 | Levy Richard S | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 7.36 | 36.8K | 15,000 | — | ↗ |
| 2024-04-01 | Daly James M | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,577 | 105.08 | 165.7K | 10,912 | — | ↗ |
| 2024-04-01 | BATE KENNETH | Director | M-Exempt | A | Common Stock | 10,000 | 9.45 | 94.5K | 11,198 | — | ↗ |
| 2024-03-21 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 970,951 | 0.00 | 97.10 | 2,493,602 | — | ↗ |
| 2024-03-11 | Dier Mardi | Officer | — | D | Market Stock Unit | 8,875 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | Waltermire Robert E. | Officer | A-Award | A | Market Stock Unit | 1,419 | 0.00 | — | 1,419 | — | ↗ |
| 2024-01-23 | Taub Rebecca | Director / Officer | A-Award | A | Market Stock Unit | 5,786 | 0.00 | — | 5,786 | — | ↗ |
| 2024-01-23 | Sibold William John | Director / Officer | A-Award | A | Market Stock Unit | 12,250 | 0.00 | — | 12,250 | — | ↗ |
| 2024-01-23 | Lynch Brian Joseph | Officer | A-Award | A | Market Stock Unit | 3,639 | 0.00 | — | 3,639 | — | ↗ |
| 2024-01-23 | Huntsman Carole | Officer | A-Award | A | Market Stock Unit | 3,639 | 0.00 | — | 3,639 | — | ↗ |
| 2024-01-23 | Howarth Alex G. | Officer | A-Award | A | Market Stock Unit | 4,803 | 0.00 | — | 4,803 | — | ↗ |
| 2024-01-16 | Waltermire Robert E. | Officer | F-InKind | D | Common Stock | 550 | 243.92 | 134.2K | 5,117 | — | ↗ |
| 2024-01-16 | Taub Rebecca | Director / Officer | F-InKind | D | Common Stock | 1,546 | 243.92 | 377.1K | 15,001 | — | ↗ |
| 2024-01-16 | Lynch Brian Joseph | Officer | F-InKind | D | Common Stock | 949 | 243.92 | 231.5K | 14,052 | — | ↗ |
| 2024-01-16 | Howarth Alex G. | Officer | F-InKind | D | Common Stock | 1,067 | 243.92 | 260.3K | 13,934 | — | ↗ |
| 2023-12-15 | Waltermire Robert E. | Officer | M-Exempt | A | Common Stock | 2,000 | 87.92 | 175.8K | 7,667 | — | ↗ |
| 2023-12-14 | Waltermire Robert E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,000 | 87.92 | 175.8K | 19,200 | — | ↗ |
| 2023-12-14 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 107 | 226.97 | 24.3K | 184,562 | — | ↗ |
| 2023-12-13 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 1,000 | 226.00 | 226.0K | 5,667 | — | ↗ |
| 2023-12-13 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 360 | 219.87 | 79.2K | 182,881 | — | ↗ |
| 2023-12-12 | Waltermire Robert E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,300 | 87.92 | 114.3K | 23,700 | — | ↗ |
| 2023-12-12 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 30 | 208.69 | 6.3K | 176,053 | — | ↗ |
| 2023-12-07 | CRAVES FRED B | Director | J-Other | D | Common Stock | 46,073 | 0.00 | — | 1,261 | — | ↗ |
| 2023-12-05 | Lynch Brian Joseph | Officer | S-Sale | D | Common Stock | 1,000 | 227.33 | 227.3K | 15,001 | — | ↗ |
| 2023-12-04 | Lynch Brian Joseph | Officer | S-Sale | D | Common Stock | 800 | 215.73 | 172.6K | 16,001 | — | ↗ |
| 2023-11-30 | Lynch Brian Joseph | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 73.75 | 221.3K | 18,000 | — | ↗ |
| 2023-11-29 | Lynch Brian Joseph | Officer | S-Sale | D | Common Stock | 1,000 | 198.40 | 198.4K | 18,001 | — | ↗ |
| 2023-11-21 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 369 | 183.16 | 67.6K | 1,608,183 | — | ↗ |
| 2023-11-20 | Huntsman Carole | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-20 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 1,206 | 185.87 | 224.2K | 1,598,604 | — | ↗ |
| 2023-11-17 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 93 | 168.78 | 15.7K | 165,955 | — | ↗ |
| 2023-11-15 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 14,018 | 161.97 | 2.27M | 1,545,775 | — | ↗ |
| 2023-11-14 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 6,022 | 152.48 | 918.2K | 1,475,058 | — | ↗ |
| 2023-11-13 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 311 | 136.91 | 42.6K | 154,189 | — | ↗ |
| 2023-10-03 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 1,522,651 | 0.00 | 152.27 | 1,522,651 | — | ↗ |
| 2023-09-11 | Sibold William John | Director / Officer | A-Award | A | Performance Restricted Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-09-08 | Sibold William John | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Levy Richard S | Director | A-Award | A | Common Stock | 1,198 | 0.00 | — | 10,298 | — | ↗ |
| 2023-06-15 | Daly James M | Director | A-Award | A | Common Stock | 1,198 | 0.00 | — | 1,198 | — | ↗ |
| 2023-06-15 | Cheong Raymond | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | CRAVES FRED B | Director | A-Award | A | Common Stock | 1,198 | 0.00 | — | 362,556 | — | ↗ |
| 2023-06-15 | BATE KENNETH | Director | A-Award | A | Common Stock | 1,198 | 0.00 | — | 1,198 | — | ↗ |
| 2023-06-15 | BAKER BROS. ADVISORS LP | Director | — | I | Common Stock | 0 | 0.00 | — | 148,821 | — | ↗ |
| 2023-03-01 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 1,928 | 273.44 | 527.2K | 8,739 | — | ↗ |
| 2023-02-28 | Waltermire Robert E. | Officer | S-Sale | D | Common Stock | 900 | 271.03 | 243.9K | 9,767 | — | ↗ |
| 2023-01-30 | CRAVES FRED B | Director | G-Gift | D | Common Stock | 3,557 | 0.00 | — | 57,062 | — | ↗ |
| 2023-01-17 | Levy Richard S | Director | S-Sale | D | Common Stock | 5,227 | 292.68 | 1.53M | 20,637 | — | ↗ |
| 2023-01-16 | Waltermire Robert E. | Officer | A-Award | A | Common Stock | 5,667 | 0.00 | — | 5,667 | — | ↗ |
| 2023-01-16 | Taub Rebecca | Officer | A-Award | A | Common Stock | 20,001 | 0.00 | — | 20,001 | — | ↗ |
| 2023-01-16 | Sukhija Remy | Officer | A-Award | A | Common Stock | 15,001 | 0.00 | — | 15,001 | — | ↗ |
| 2023-01-16 | Lynch Brian Joseph | Officer | A-Award | A | Common Stock | 15,001 | 0.00 | — | 15,001 | — | ↗ |
| 2023-01-16 | Howarth Alex G. | Officer | A-Award | A | Common Stock | 15,001 | 0.00 | — | 15,001 | — | ↗ |
| 2023-01-16 | FRIEDMAN PAUL A | Director | F-InKind | D | Common Stock | 2,254 | 243.92 | 549.8K | 20,001 | — | ↗ |
| 2023-01-03 | Lynch Brian Joseph | Officer | S-Sale | D | Common Stock | 2,628 | 282.97 | 743.6K | 4,916 | — | ↗ |
| 2022-12-23 | Sukhija Remy | Officer | S-Sale | D | Common Stock | 811 | 275.70 | 223.6K | 8,923 | — | ↗ |
| 2022-12-23 | Lynch Brian Joseph | Officer | S-Sale | D | Common Stock | 361 | 277.77 | 100.3K | 1,700 | — | ↗ |
| 2022-08-10 | Lynch Brian Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 73.75 | 1.84M | 25,000 | — | ↗ |
| 2022-06-16 | MILLIGAN DAVID V | Director | A-Award | A | Stock Option (Right to buy) | 9,470 | 0.00 | — | 9,470 | — | ↗ |
| 2022-06-16 | Levy Richard S | Director | A-Award | A | Stock Option (Right to buy) | 9,470 | 0.00 | — | 9,470 | — | ↗ |
| 2022-06-16 | Gollust Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 9,470 | 0.00 | — | 9,470 | — | ↗ |
| 2022-06-16 | Daly James M | Director | A-Award | A | Stock Option (Right to Buy) | 9,470 | 0.00 | — | 9,470 | — | ↗ |
| 2022-06-16 | CRAVES FRED B | Director | A-Award | A | Stock Option (Right to Buy) | 9,470 | 0.00 | — | 9,470 | — | ↗ |
| 2022-06-16 | BATE KENNETH | Director | A-Award | A | Stock Option (Right to Buy) | 9,470 | 65.06 | 616.1K | 9,470 | — | ↗ |
| 2022-02-24 | Waltermire Robert E. | Officer | A-Award | A | Call Option | 12,250 | 87.09 | 1.07M | 12,250 | — | ↗ |
| 2022-02-22 | Taub Rebecca | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 61,500 | 87.09 | 5.36M | 61,500 | — | ↗ |
| 2022-02-22 | Sukhija Remy | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 87.09 | 3.92M | 45,000 | — | ↗ |
| 2022-02-22 | Lynch Brian Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 87.09 | 3.92M | 45,000 | — | ↗ |
| 2022-02-22 | Howarth Alex G. | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 87.09 | 3.92M | 45,000 | — | ↗ |
| 2022-02-22 | FRIEDMAN PAUL A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 87.09 | 6.10M | 70,000 | — | ↗ |
| 2022-02-19 | Lynch Brian Joseph | Officer | — | D | Stock Option (Right to Buy) | 19,000 | 134.25 | 2.55M | 0 | — | ↗ |
| 2021-12-31 | CRAVES FRED B | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 18,000 | — | ↗ |
| 2021-12-03 | CRAVES FRED B | Director / 10% Owner | J-Other | D | Common Stock | 750,270 | 0.00 | — | 1,510,521 | — | ↗ |
| 2021-12-03 | BAY CITY CAPITAL LLC | 10% Owner | J-Other | D | Common Stock | 750,270 | 0.00 | — | 1,510,521 | — | ↗ |
| 2021-11-01 | Howarth Alex G. | Officer | A-Award | A | Stock Option (Right to Buy) | 5,000 | 81.95 | 409.8K | 5,000 | — | ↗ |
| 2021-08-02 | Waltermire Robert E. | Officer | A-Award | A | Call Option | 35,000 | 87.92 | 3.08M | 35,000 | — | ↗ |
| 2021-06-17 | MILLIGAN DAVID V | Director | A-Award | A | Stock Option (Right to buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-06-17 | Levy Richard S | Director | A-Award | A | Stock Option (Right to buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-06-17 | Gollust Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-06-17 | Daly James M | Director | A-Award | A | Stock Option (Right to Buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-06-17 | CRAVES FRED B | Director | A-Award | A | Stock Option (Right to Buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-06-17 | BATE KENNETH | Director | A-Award | A | Stock Option (Right to Buy) | 12,489 | 105.08 | 1.31M | 12,489 | — | ↗ |
| 2021-05-17 | Howarth Alex G. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 134.00 | 8.71M | 65,000 | — | ↗ |
| 2021-02-22 | Taub Rebecca | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 44,000 | 119.49 | 5.26M | 44,000 | — | ↗ |
| 2021-02-22 | Sukhija Remy | Officer | A-Award | A | Stock Option (Right to Buy) | 24,000 | 119.49 | 2.87M | 24,000 | — | ↗ |
| 2021-02-22 | Schneebaum Marc R | Officer | A-Award | A | Stock Option (Right to Buy) | 32,000 | 119.49 | 3.82M | 32,000 | — | ↗ |
| 2021-02-22 | Lynch Brian Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 32,000 | 119.49 | 3.82M | 32,000 | — | ↗ |
| 2021-02-22 | FRIEDMAN PAUL A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 119.49 | 5.97M | 50,000 | — | ↗ |
| 2020-12-31 | CRAVES FRED B | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
| 2020-12-01 | BAY CITY CAPITAL LLC | 10% Owner | J-Other | D | Common Stock | 43,537 | 0.00 | — | 2,310,521 | — | ↗ |
| 2020-09-04 | CRAVES FRED B | Director / 10% Owner | J-Other | D | Common Stock | 1,468,350 | 0.00 | — | 2,260,791 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-503.7K
Shares Outstanding
22.94M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Bill Sibold President and Chief Executive Officer | 889.6K | — | 7.56M | 2.81M | 950.5K | 10.4K | 12.21M | 84.85% | ↗ |
| 2 | 2024 | Mardi Dier Executive Vice President and Chief Financial Officer | 464.7K | — | 5.68M | 2.23M | 296.7K | 80.4K | 8.75M | 90.38% | ↗ |
| 3 | 2024 | Rebecca Taub, M.D. Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | 596.2K | — | 3.57M | 1.32M | 426.0K | 50.0K | 5.97M | 82.03% | ↗ |
| 4 | 2024 | Alex Howarth Former Senior Vice President and Chief Financial Officer | 294.5K | — | 2.96M | 1.10M | — | 884.8K | 5.24M | 77.51% | ↗ |
| 5 | 2024 | Shannon Kelley Executive Vice President and Chief Legal Counsel | 441.7K | — | 1.95M | 1.95M | 325.9K | 6.2K | 4.67M | 83.44% | ↗ |
| 6 | 2024 | Brian J. Lynch Former Senior Vice President and General Counsel | 380.1K | — | 2.25M | 833.3K | — | 792.1K | 4.25M | 72.42% | ↗ |
| 7 | 2024 | Carole Huntsman Executive Vice President and Chief Commercial Officer | 525.0K | — | 2.25M | 833.3K | 335.5K | 10.4K | 3.95M | 77.95% | ↗ |
| 8 | 2023 | Bill Sibold President and Chief Executive Officer | 275.4K | 520.0K | 31.21M | — | 268.0K | — | 32.27M | 96.70% | ↗ |
| 9 | 2023 | Paul A. Friedman, M.D. Former Chief Executive Officer | 498.8K | — | 8.00M | — | — | 1.06M | 9.56M | 83.65% | ↗ |
| 10 | 2023 | Remy Sukhija Former Senior Vice President, Chief Commercial Officer | 387.7K | — | 4.50M | — | — | 2.47M | 7.36M | 61.12% | ↗ |
| 11 | 2023 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 574.1K | — | 6.00M | — | 354.0K | — | 6.93M | 86.60% | ↗ |
| 12 | 2023 | Rebecca Taub, M.D. Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | 574.1K | — | 6.00M | — | 354.0K | — | 6.93M | 86.60% | ↗ |
| 13 | 2023 | Brian J. Lynch Former Senior Vice President and General Counsel | 501.6K | — | 4.50M | — | 247.0K | 18.0K | 5.27M | 85.44% | ↗ |
| 14 | 2023 | Alex Howarth Former Senior Vice President and Chief Financial Officer | 498.8K | — | 4.50M | — | 246.0K | 17.2K | 5.26M | 85.52% | ↗ |
| 15 | 2023 | Carole Huntsman Executive Vice President and Chief Commercial Officer | 61.9K | — | 1.49M | 1.56M | 32.0K | 79.00 | 3.14M | 97.01% | ↗ |
| 16 | 2023 | Carole Huntsman Chief Commercial Officer | 61.9K | — | 1.49M | 1.56M | 32.0K | 79.00 | 3.14M | 97.01% | ↗ |
| 17 | 2022 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 658.0K | — | — | 4.24M | 497.5K | — | 5.40M | 78.58% | ↗ |
| 18 | 2022 | Paul A. Friedman, M.D. Former Chief Executive Officer | 658.0K | — | — | 4.24M | 497.5K | — | 5.40M | 78.58% | ↗ |
| 19 | 2022 | Brian J. Lynch Senior Vice President and General Counsel | 467.6K | — | — | 3.99M | 282.8K | 13.3K | 4.76M | 83.95% | ↗ |
| 20 | 2022 | Brian J. Lynch Former Senior Vice President and General Counsel | 467.6K | — | — | 3.99M | 282.8K | 13.3K | 4.76M | 83.95% | ↗ |
| 21 | 2022 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 535.2K | — | — | 3.73M | 404.6K | — | 4.66M | 79.85% | ↗ |
| 22 | 2022 | Rebecca Taub, M.D. Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | 535.2K | — | — | 3.73M | 404.6K | — | 4.66M | 79.85% | ↗ |
| 23 | 2022 | Remy Sukhija Former Senior Vice President, Chief Commercial Officer | 482.8K | — | — | 2.73M | 292.0K | 10.4K | 3.51M | 77.64% | ↗ |
| 24 | 2022 | Remy Sukhija Senior Vice President, Chief Commercial Officer | 482.8K | — | — | 2.73M | 292.0K | 10.4K | 3.51M | 77.64% | ↗ |
| 25 | 2022 | Alex Howarth Former Senior Vice President and Chief Financial Officer | 465.6K | — | — | 2.73M | 281.3K | 10.4K | 3.48M | 78.26% | ↗ |
| 26 | 2022 | Alex Howarth Senior Vice President and Chief Financial Officer | 465.6K | — | — | 2.73M | 281.3K | 10.4K | 3.48M | 78.26% | ↗ |
| 27 | 2021 | Alex Howarth Senior Vice President and Chief Financial Officer | 281.3K | 75.0K | — | 6.53M | 241.2K | 7.9K | 7.13M | 91.51% | ↗ |
| 28 | 2021 | Alex Howarth Former Senior Vice President and Chief Financial Officer | 281.3K | 75.0K | — | 6.53M | 241.2K | 7.9K | 7.13M | 91.51% | ↗ |
| 29 | 2021 | Paul A. Friedman, M.D. Former Chief Executive Officer | 627.7K | — | — | 4.27M | 423.2K | — | 5.32M | 80.24% | ↗ |
| 30 | 2021 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 627.7K | — | — | 4.27M | 423.2K | — | 5.32M | 80.24% | ↗ |
| 31 | 2021 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 510.5K | — | — | 3.76M | 344.2K | — | 4.61M | 81.46% | ↗ |
| 32 | 2021 | Marc R. Schneebaum Former Senior Vice President, Chief Financial Officer | 369.8K | — | — | 2.73M | 91.1K | 512.7K | 3.70M | 73.72% | ↗ |
| 33 | 2021 | Brian J. Lynch Former Senior Vice President and General Counsel | 445.3K | — | — | 2.73M | 240.6K | 13.3K | 3.43M | 79.62% | ↗ |
| 34 | 2021 | Brian J. Lynch Senior Vice President and General Counsel | 445.3K | — | — | 2.73M | 240.6K | 13.3K | 3.43M | 79.62% | ↗ |
| 35 | 2021 | Remy Sukhija Senior Vice President, Chief Commercial Officer | 461.3K | — | — | 2.05M | 248.4K | 10.4K | 2.77M | 73.99% | ↗ |
| 36 | 2021 | Remy Sukhija Former Senior Vice President, Chief Commercial Officer | 461.3K | — | — | 2.05M | 248.4K | 10.4K | 2.77M | 73.99% | ↗ |
| 37 | 2020 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 603.5K | — | — | 3.47M | 463.4K | — | 4.54M | 76.48% | ↗ |
| 38 | 2020 | Brian J. Lynch Senior Vice President and General Counsel | 425.4K | — | — | 3.75M | 260.9K | 11.7K | 4.45M | 84.31% | ↗ |
| 39 | 2020 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 490.8K | — | — | 3.05M | 339.2K | — | 3.88M | 78.62% | ↗ |
| 40 | 2020 | Remy Sukhija Senior Vice President, Chief Commercial Officer | 337.5K | 100.0K | — | 2.72M | 274.7K | 2.7K | 3.44M | 79.21% | ↗ |
| 41 | 2020 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 435.0K | — | — | 2.22M | 267.2K | 18.4K | 2.94M | 75.49% | ↗ |
| 42 | 2020 | Marc R. Schneebaum Former Senior Vice President, Chief Financial Officer | 435.0K | — | — | 2.22M | 267.2K | 18.4K | 2.94M | 75.49% | ↗ |
| 43 | 2019 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 584.0K | — | — | 5.12M | 387.2K | — | 6.09M | 84.06% | ↗ |
| 44 | 2019 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer, | 463.9K | — | — | 4.53M | 274.8K | — | 5.27M | 85.98% | ↗ |
| 45 | 2019 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 463.9K | — | — | 4.53M | 274.8K | — | 5.27M | 85.98% | ↗ |
| 46 | 2019 | Brian J. Lynch Senior Vice President and General Counsel | 358.6K | — | — | 3.51M | 192.6K | 10.6K | 4.07M | 86.19% | ↗ |
| 47 | 2019 | Brian J Lynch Senior Vice President and General Counsel | 358.6K | — | — | 3.51M | 192.6K | 10.6K | 4.07M | 86.19% | ↗ |
| 48 | 2019 | Marc R. Schneebaum Former Senior Vice President, Chief Financial Officer | 421.0K | — | — | 2.87M | 223.3K | 20.0K | 3.53M | 81.19% | ↗ |
| 49 | 2019 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 421.0K | — | — | 2.87M | 223.3K | 20.0K | 3.53M | 81.19% | ↗ |
| 50 | 2018 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 416.7K | — | — | 4.91M | 304.5K | — | 5.63M | 87.19% | ↗ |
| 51 | 2018 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer | 385.4K | — | — | 3.73M | 225.3K | — | 4.34M | 85.93% | ↗ |
| 52 | 2018 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer, | 385.4K | — | — | 3.73M | 225.3K | — | 4.34M | 85.93% | ↗ |
| 53 | 2018 | Rebecca Taub, M.D. Chief Medical Officer, Executive Vice President, Research & Development | 385.4K | — | — | 3.73M | 225.3K | — | 4.34M | 85.93% | ↗ |
| 54 | 2018 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 380.3K | — | — | 2.75M | 222.3K | 15.3K | 3.37M | 81.64% | ↗ |
| 55 | 2017 | Paul A. Friedman, M.D. Chief Executive Officer | 400.0K | 335.0K | 629.4K | — | — | 558.00 | 1.36M | 46.11% | ↗ |
| 56 | 2017 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 400.0K | — | — | 629.4K | 335.0K | 558.00 | 1.36M | 46.11% | ↗ |
| 57 | 2017 | Rebecca Taub, M.D. President, Research & Development and Chief Medical Officer, | 370.0K | — | — | 473.3K | 247.9K | 558.00 | 1.09M | 43.35% | ↗ |
| 58 | 2017 | Rebecca Taub, M.D. Chief Medical Officer, Executive Vice President, Research & Development | 370.0K | — | — | 473.3K | 247.9K | 558.00 | 1.09M | 43.35% | ↗ |
| 59 | 2017 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 365.0K | — | — | 346.4K | 244.6K | 14.3K | 970.3K | 35.70% | ↗ |
| 60 | 2016 | Paul A. Friedman, M.D. Chairman and Chief Executive Officer | 175.9K | — | 1.45M | 2.28M | 84.0K | 465.00 | 3.99M | 93.47% | ↗ |
| 61 | 2016 | Paul A. Friedman, M.D. Chief Executive Officer | 175.9K | 84.0K | 1.45M | 2.28M | — | 465.00 | 3.99M | 93.47% | ↗ |
| 62 | 2016 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 365.0K | — | 393.8K | 729.1K | 146.5K | 51.2K | 1.69M | 66.62% | ↗ |
| 63 | 2016 | Rebecca Taub, M.D. Chief Medical Officer, Executive Vice President, Research & Development | 162.7K | — | 289.4K | 1.14M | 62.2K | 465.00 | 1.65M | 86.38% | ↗ |
| 64 | 2016 | Chen Schor Former President and Chief Executive Officer | 297.5K | 178.5K | 351.3K | — | — | 810.8K | 1.64M | 21.45% | ↗ |
| 65 | 2016 | Wendy E. Rieder, Esq. Senior Vice President, General Counsel | 178.5K | 71.4K | 162.2K | — | — | 330.8K | 742.9K | 21.83% | ↗ |
| 66 | 2015 | Chen Schor Former President and Chief Executive Officer | 471.0K | 306.0K | 360.0K | 1.90M | — | 8.0K | 3.04M | 74.22% | ↗ |
| 67 | 2015 | Wendy E. Rieder, Esq. Senior Vice President, General Counsel | 303.0K | 122.4K | — | 486.6K | — | 8.0K | 902.0K | 53.95% | ↗ |
| 68 | 2015 | Marc R. Schneebaum Senior Vice President, Chief Financial Officer | 346.7K | 146.0K | — | 169.6K | — | 28.0K | 690.3K | 24.58% | ↗ |
| 69 | 2014 | Anne Whitaker | 183.3K | 380.0K | 2.00M | 2.45M | — | 101.4K | 5.11M | 87.00% | ↗ |
| 70 | 2014 | Chen Schor | 27.5K | 50.0K | 427.5K | 1.04M | — | — | 1.55M | 94.99% | ↗ |
| 71 | 2014 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 378.3K | 152.0K | — | 709.1K | — | — | 1.24M | 57.21% | ↗ |
| 72 | 2014 | Arthur J. McMahon | 276.7K | 111.2K | — | 577.5K | — | 5.3K | 970.7K | 59.49% | ↗ |
| 73 | 2014 | Marc Schneebaum | 21.0K | — | 213.8K | 520.9K | — | — | 755.7K | 97.22% | ↗ |
| 74 | 2014 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 288.8K | 69.6K | — | 336.4K | — | 7.8K | 702.6K | 47.87% | ↗ |
| 75 | 2014 | Safi R. Bahcall, Ph.D. Former President and Chief Executive Officer | 88.7K | — | — | — | — | 431.9K | 520.6K | 0.00% | ↗ |
| 76 | 2014 | Keith R. Gollust | — | — | — | — | — | — | — | — | ↗ |
| 77 | 2013 | Sumant Ramachandra, M.D., Ph.D | 109.2K | — | 719.3K | 1.73M | — | 1.8K | 2.56M | 95.67% | ↗ |
| 78 | 2013 | Safi R. Bahcall, Ph.D. Former President and Chief Executive Officer | 516.7K | — | — | 1.78M | — | 31.9K | 2.33M | 76.45% | ↗ |
| 79 | 2013 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 368.3K | 118.0K | — | 774.1K | — | — | 1.26M | 61.41% | ↗ |
| 80 | 2013 | Amar Singh Former Senior Vice President, Chief Business Officer | 313.3K | — | — | 569.0K | — | 28.9K | 911.2K | 62.44% | ↗ |
| 81 | 2013 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 281.7K | 68.0K | — | 406.6K | — | 7.7K | 763.9K | 53.22% | ↗ |
| 82 | 2013 | Keith S. Ehrlich, C.P.A Vice President, Finance and Administration, Chief Financial Officer | 281.7K | 68.0K | — | 406.6K | — | 7.7K | 763.9K | 53.22% | ↗ |
| 83 | 2013 | Steven Bernitz | 12.1K | — | 108.5K | 530.9K | — | — | 651.5K | 98.14% | ↗ |
| 84 | 2012 | Safi R. Bahcall, Ph.D. Former President and Chief Executive Officer | 459.2K | 250.0K | — | — | — | 80.7K | 2.06M | 0.00% | ↗ |
| 85 | 2012 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 459.2K | 250.0K | — | 1.27M | — | 80.7K | 2.06M | 61.65% | ↗ |
| 86 | 2012 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 357.5K | 144.0K | — | 398.7K | — | — | 900.2K | 44.29% | ↗ |
| 87 | 2012 | Amar Singh Former Senior Vice President, Chief Business Officer | 304.2K | 122.0K | — | 367.7K | — | 10.3K | 804.2K | 45.73% | ↗ |
| 88 | 2012 | Amar Singh Senior Vice President, Chief Business Officer | 304.2K | 122.0K | — | 367.7K | — | 10.3K | 804.2K | 45.73% | ↗ |
| 89 | 2012 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 273.3K | 82.5K | — | 261.2K | — | 7.5K | 624.6K | 41.83% | ↗ |
| 90 | 2012 | Keith S. Ehrlich, C.P.A Vice President, Finance and Administration, Chief Financial Officer | 273.3K | 82.5K | — | 261.2K | — | 7.5K | 624.6K | 41.83% | ↗ |
| 91 | 2012 | Wendy Rieder | 271.7K | 81.9K | — | 261.2K | — | 8.2K | 622.9K | 41.93% | ↗ |
| 92 | 2011 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 425.8K | 193.5K | 60.7K | 850.0K | — | 80.5K | 1.61M | 56.55% | ↗ |
| 93 | 2011 | Safi R. Bahcall, Ph.D. Former President and Chief Executive Officer | 425.8K | 193.5K | 60.7K | 850.0K | — | 80.5K | 1.61M | 56.55% | ↗ |
| 94 | 2011 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 340.8K | 138.0K | 38.4K | 425.0K | — | — | 942.2K | 49.18% | ↗ |
| 95 | 2011 | Keizo Koya, Ph.D.* Senior Vice President, Drug Development | 307.5K | 111.2K | 36.0K | 247.4K | — | 6.1K | 708.2K | 40.01% | ↗ |
| 96 | 2011 | Keith S. Ehrlich, C.P.A Vice President, Finance and Administration, Chief Financial Officer | 263.7K | 71.6K | 23.1K | 178.0K | — | 5.2K | 541.6K | 37.15% | ↗ |
| 97 | 2011 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 263.7K | 71.6K | 23.1K | 178.0K | — | 5.2K | 541.6K | 37.15% | ↗ |
| 98 | 2011 | Amar Singh Senior Vice President, Chief Business | 300.0K | 78.0K | — | — | — | 7.4K | 385.4K | 0.00% | ↗ |
| 99 | 2011 | Amar Singh Former Senior Vice President, Chief Business Officer | 300.0K | 78.0K | — | — | — | 7.4K | 385.4K | 0.00% | ↗ |
| 100 | 2011 | Amar Singh Senior Vice President, Chief Business Officer | 300.0K | 78.0K | — | — | — | 7.4K | 385.4K | 0.00% | ↗ |
| 101 | 2010 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 401.7K | 162.0K | 55.6K | — | — | 82.3K | 1.23M | 4.54% | ↗ |
| 102 | 2010 | Keizo Koya, Ph.D. Senior Vice President, Drug Development | 297.7K | 96.0K | 33.1K | — | — | 8.3K | 685.4K | 4.82% | ↗ |
| 103 | 2010 | Keizo Koya, Ph.D.* Senior Vice President, Drug Development | 297.7K | 96.0K | 33.1K | 250.5K | — | 8.3K | 685.4K | 41.36% | ↗ |
| 104 | 2010 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 310.0K | 102.4K | 30.1K | 227.7K | — | — | 670.2K | 38.46% | ↗ |
| 105 | 2010 | Amar Singh Senior Vice President, Chief Business Officer | 27.3K | — | 106.3K | 516.0K | — | — | 649.6K | 95.80% | ↗ |
| 106 | 2010 | Amar Singh Senior Vice President, Chief Business | 27.3K | — | 106.3K | 516.0K | — | — | 649.6K | 95.80% | ↗ |
| 107 | 2010 | Amar Singh Senior Vice President, Chief Business Officer | 27.3K | — | 106.3K | 516.0K | — | — | 649.6K | 95.80% | ↗ |
| 108 | 2010 | Keith S. Ehrlich, C.P.A Vice President, Finance and Administration, Chief Financial Officer | 255.0K | 86.2K | 21.2K | 125.4K | — | 8.3K | 496.0K | 29.56% | ↗ |
| 109 | 2010 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 255.0K | 86.2K | 21.2K | 125.4K | — | 8.3K | 496.0K | 29.56% | ↗ |
| 110 | 2010 | Keith S. Ehrlich Vice President, Finance and Administration, Chief Financial Officer | 255.0K | 86.2K | 21.2K | — | — | 8.3K | 496.0K | 4.28% | ↗ |
| 111 | 2009 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 385.0K | 123.6K | — | — | — | 82.7K | 869.2K | 0.00% | ↗ |
| 112 | 2009 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 248.3K | 66.8K | — | 294.2K | — | 36.7K | 646.1K | 45.54% | ↗ |
| 113 | 2009 | Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 248.3K | 66.8K | — | 294.2K | — | 36.7K | 646.1K | 45.54% | ↗ |
| 114 | 2009 | Michael P. Bailey | 300.0K | 107.0K | — | 88.9K | — | 4.2K | 500.1K | 17.78% | ↗ |
| 115 | 2009 | Jeremy G. Chadwick, Ph.D. | 275.0K | 98.1K | — | 81.5K | — | 8.3K | 462.9K | 17.61% | ↗ |
| 116 | 2009 | Keizo Koya, Ph.D.* Senior Vice President, Drug Development | 286.0K | 73.4K | — | — | — | 8.7K | 452.9K | 0.00% | ↗ |
| 117 | 2009 | Keizo Koya, Ph.D. Senior Vice President, Drug Development | 286.0K | 73.4K | — | — | — | 8.7K | 452.9K | 0.00% | ↗ |
| 118 | 2009 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 245.0K | 71.7K | — | 58.7K | — | 7.4K | 382.7K | 15.32% | ↗ |
| 119 | 2009 | Keith S. Ehrlich Vice President, Finance and Administration, Chief Financial Officer | 245.0K | 71.7K | — | — | — | 7.4K | 382.7K | 0.00% | ↗ |
| 120 | 2008 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 380.0K | — | 266.9K | 434.4K | — | 71.4K | 1.15M | 60.84% | ↗ |
| 121 | 2008 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 380.0K | — | — | — | — | 71.4K | 1.03M | 0.00% | ↗ |
| 122 | 2008 | Keizo Koya, Ph.D. Senior Vice President, Drug Development | 283.3K | — | 213.5K | 215.5K | — | 7.7K | 720.0K | 59.58% | ↗ |
| 123 | 2008 | James G. Barsoum, Ph.D. | 269.2K | — | 213.5K | 197.9K | — | 7.7K | 688.3K | 59.78% | ↗ |
| 124 | 2008 | Eric W. Jacobson, M.D. | 298.3K | — | 87.5K | 256.5K | — | 8.0K | 650.3K | 52.89% | ↗ |
| 125 | 2008 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 242.5K | — | 133.4K | 163.8K | — | 7.1K | 546.9K | 54.35% | ↗ |
| 126 | 2008 | Keizo Koya, Ph.D. Senior Vice President, Drug Development | 283.3K | — | — | — | — | 7.7K | 534.5K | 0.00% | ↗ |
| 127 | 2008 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 242.5K | — | — | 167.5K | — | 7.1K | 417.2K | 40.16% | ↗ |
| 128 | 2008 | Keith S. Ehrlich Vice President, Finance and Administration, Chief Financial Officer | 242.5K | — | — | — | — | 7.1K | 417.2K | 0.00% | ↗ |
| 129 | 2007 | Safi R. Bahcall, Ph.D. President and Chief Executive Officer | 352.5K | 177.5K | — | — | — | 80.5K | 884.8K | 0.00% | ↗ |
| 130 | 2007 | Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer | 228.3K | 69.0K | — | 134.8K | — | 6.5K | 438.6K | 30.73% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William J. Sibold | Chief Executive Officer, President & Director | 2M | male |
| Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director | 1M | — |
| Mardi C. Dier | Executive Vice President & Chief Financial Officer | 1M | female |
| Carole Huntsman | Executive Vice President & Chief Commercial Officer | 1M | female |
| David Soergel | Executive VP & Chief Medical Officer | 1M | — |
| Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary | 1M | female |
| Tina E. Ventura | Chief Investor Relations Officer | — | female |
| Clint Wallace | Executive Vice President & Chief Human Resources Officer | — | male |
| Mark Underwood | Executive Vice President of Business Planning & Operations | — | male |
| Rita Thakkar | Senior VP & Chief Accounting Officer | — | female |
| Ronald Filippo | Executive Vice President & Chief Information Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-04-10 | 2023-05-19 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDGL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
